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Abstract 
Background: Early diagnosis and treatment of pulmonary tuberculosis (PTB) is essential for an effective control of 
the tuberculosis (TB) epidemic. Delayed diagnosis and treatment of TB increases the chance of complications and 
mortality for the patients, and enhances TB transmission in the population. Therefore, the aim of this study was to 
characterize patient, healthcare and total delay in diagnosing PTB and assess the effect of clinical and sociodemo-
graphic factors on the time until first contact with healthcare or reaching a PTB diagnosis.
Methods: Retrospective cohort study that included active PTB patients notified in the National Tuberculosis Surveil-
lance System (SVIG-TB), between 2008 and 2017. Descriptive statistics, Kaplan-Meier estimates, logrank test and Cox 
proportional hazards model were used to characterize patient, healthcare and total delay and estimate the effect of 
clinical and sociodemographic variables on these delays. Significance level was set at 0.05.
Results: Median patient, healthcare and total delays was 37 days (Interquartile range (IQR): 19–71), 8 days (IQR: 1–32) 
and 62 days (IQR: 38–102), respectively.
The median patient delay showed a constant increase, from 33 days in 2008 to 44 days in 2017. The median total delay 
presented a similar trend, increasing from 59 days in 2008 to 70 days in 2017. Healthcare delay remained constant 
during the study period. More than half of the PTB cases (82.9%) had a delay > 1 month between symptom onset and 
diagnosis.
In the final Cox model, alcohol abuse, unemployment and being from a high TB incidence country were factors sig-
nificantly associated with longer patient delay, while being female, having more than 45 years, oncologic and respira-
tory diseases were associated with longer healthcare delay. Being female, having more than 45 years and being from a 
high TB incidence country were associated with longer total delay.
Conclusions: Patient delay and total delay have increased in recent years. Older patients, patients with alcohol prob-
lems, other comorbidities, unemployed or from countries with high TB incidence would benefit from the develop-
ment of specific public health strategies that could help reduce the delay in TB diagnosis observed in our study.
This study emphasizes the need to promote awareness of TB in the general population and among the healthcare 
community, especially at ambulatory care level, in order to reduce the gap between beginning of symptoms and TB 
diagnosis.
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Background
Tuberculosis (TB) remains one of the greatest public 
health challenges of our time. In 2019, an estimated 
10.0 million people had TB and 1.4 million people died 
of the disease worldwide, making TB the main cause of 
mortality and morbidity through infection [1]. Portugal 
has seen a steady reduction in the number of notified 
TB cases during the last decade [2] but still has one of 
the highest TB incidence rates in the European Union 
(EU), only surpassed by some Eastern European coun-
tries [3]. Therefore, despite advances in the control of 
the TB epidemic on a global scale, the road is still long 
and fraught with challenges until TB elimination can be 
achieved as intended by the End TB Strategy, a strategy 
of the World Health Organization (WHO) to control 
and eliminate the TB epidemic by 2035 [4, 5].
TB usually presents with nonspecific symptoms that 
can easily be mistaken for other prevalent febrile infec-
tions, especially in the early stages of the disease. As 
early-stage symptoms are not usually disabling and 
allow to continue with day-to-day activities, the disease 
may progress for weeks or months before becoming 
severe enough for patients to seek care or be diagnosed 
with active TB [6]. During this time, people who come 
into close contact with the patient are at risk of being 
infected. 
Most TB control programs adopt the passive case 
finding as the predominant approach to detect TB 
cases, which means that cases are detected when peo-
ple experience symptoms that lead them to seek the 
healthcare services [7]. Successful case detection also 
relies on health care systems capacity to quickly diag-
nose and initiate treatment [8]. Therefore, early diagno-
sis and prompt TB treatment is essential for an effective 
TB control program [9, 10] since delaying the diagno-
sis worsens illness severity, prolongs patient suffer-
ing, increases the risk of patient death, and enables the 
transmission within the community [8]. Delayed diag-
nosis and TB treatment occur in both high and low TB 
prevalence countries [8, 11].
These delays can be linked to both patient and 
the  healthcare system. Patients can postpone seek-
ing medical aid (patient delay) or the healthcare pro-
viders may not recognize and diagnose a TB case in a 
timely manner (healthcare delay) [11]. Although there 
is no universally accepted period for total delay (sum of 
patient and healthcare delays), it is generally accepted 
that total delay should not exceed one month for the 
majority of TB patients [12, 13].
There are several studies on TB diagnosis and treat-
ment delay with the majority conducted in low and 
middle-income countries [11, 14–18], where the TB 
epidemic, socioeconomic and healthcare systems are 
substantially different from the high income countries. 
Several demographic, socioeconomic and clinical fac-
tors have been identified in these studies that may impact 
negatively the time to diagnosis and beginning of treat-
ment [10, 11, 15, 16, 18–20], such as unfavorable social 
and economic conditions, accessibility or quality of ser-
vices, education, age, gender, human immunodeficiency 
virus (HIV) co-infection or alcohol and drug addiction 
[8, 15].
Some studies [21–23] have already been carried out in 
Portugal that analyze the delay in diagnosing TB cases, 
but a broader notion of the evolution of delays over the 
years and a better understanding of the factors that influ-
ence delays, whether at the patient, healthcare system or 
global level, are needed. Identifying these factors could 
support the improvement of health services and assist in 
the development of strategies to prevent and control the 
spread of the disease more effectively.
Therefore, the aim of this study was to characterize 
patient, healthcare and total delay in diagnosing pulmo-
nary TB (PTB) and assess the effect of clinical and soci-
odemographic factors on the time until first contact with 
healthcare or reaching a PTB diagnosis.
Methods
Study design and data source
Retrospective cohort study that used data from active 
PTB cases notified in the Portuguese National Tuber-
culosis Surveillance System (SVIG-TB). SVIG-TB is a 
clinical-based notification system in which the informa-
tion is generated by direct collection of information from 
healthcare providers, who notify the case at the time of 
diagnosis and update the information during follow-up, 
to a network that aggregates the information at a national 
level [24].
Study data
The study included all PTB cases notified in the SVIG-TB 
database between 2008 and 2017. Were excluded from 
the study patients that: (i) were not identified through 
passive case finding, as these patients did not seek medi-
cal care for their symptoms and were identified due to 
other reasons (e.g., contact tracing); (ii) had a total delay 
of more than one year (> 365 days), as it is unlikely that 
such a long delay would occur, suggesting the possibility 
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of errors in the introduction of the dates that define the 
time until diagnosis, either when filling out the forms 
or when entering the information in the database; (iii) 
had absent or incorrect dates for symptoms onset, first 
healthcare contact and/or diagnosis, as it prevents estab-
lishing patient, healthcare and/or total delay for these 
patients.
For the present study, three outcomes were considered: 
patient delay, healthcare delay and total delay.
Patient delay was defined as the time between the 
date of onset of symptoms possibly related to PTB and 
the patient’s first medical appointment, and healthcare 
delay was defined as the period between the first medi-
cal appointment and the PTB diagnosis date [6, 11, 25]. 
Total delay was defined as the period between the date of 
symptoms onset and the diagnosis date (sum of patient 
and healthcare delays) [6, 11, 25].
The clinical and sociodemographic variables comprised 
in the analysis were selected based on the literature [11, 
15, 23], and included sex (male/female); age at diagnosis; 
country of origin (Portugal/country of low TB incidence 
(< 20/100000 population)/country of high TB incidence 
(> 20/100000 population) [4, 26]); comorbidities [chronic 
renal failure on dialysis (yes/no), oncologic diseases (yes/
no), inflammatory diseases (yes/no), respiratory diseases 
(yes/no), diabetes (yes/no) and HIV infection (yes/no)], 
substance abuse [alcohol abuse (yes/no) and drug abuse 
(yes/no)], homeless (yes/no); community residence (yes/
no); unemployment (yes/no); health professional (yes/
no).
Statistical analysis
A descriptive analysis of the study population was per-
formed using absolute and relative frequencies for cat-
egorical variables and median and interquartile range 
(IQR = Quartile 1 - Quartile 3) for numerical variables. 
The distribution of variables between groups (included 
and excluded) was compared using the chi-square test, 
as a way to assess selection bias. Total delay and its com-
ponents were categorized into four groups: ≤1 month, 
between 1 and 2 months, 2 and 3 months and > 3 months
Three different analyses for each outcome (patient 
delay, healthcare delay and total delay) were performed. 
Since the event occurred for each patient, the study did 
not present censored times. To assess the effect of clini-
cal and sociodemographic variables on the time until the 
event of interest (first contact with healthcare or PTB 
diagnosis), Kaplan-Meier estimator [27] and the logrank 
test [28] were used to compare the survival curves 
between groups in the same variable. Significant vari-
ables (p-value ≤0.05) were considered for the multivari-
able analyses.
Cox proportional hazards model [29] was used to esti-
mate the effect of the clinical and sociodemographic 
variables on the time until the event of interest. All signif-
icant variables in the logrank test were initially included 
in the model. The final model was derived using a back-
ward stepwise approach, keeping only variables with a 
p-value ≤0.05 in the final model.
Hazard ratios (HR) with 95% confidence intervals 
(95%CI) were used as the measure of association, with 
HR values > 1 constituting a higher risk of having the 
event per unit of time. In other words, HR > 1 repre-
sented a shorter time to approach the healthcare services 
(patient delay) or being diagnosed (healthcare and total 
delay), while HR < 1 represented a longer time to event 
and, therefore, higher patient, healthcare or total delays.
The proportional hazards assumption was assessed 
through the Schoenfeld residuals. The linear correla-
tion between the residuals and time was tested and scat-
terplots were drawn to check the proportional hazards 
assumption.
All statistical analyses were performed using IBM® 




From 2008 to 2017, 15,359 cases of active PTB identi-
fied through passive case-finding were notified to SVIG-
TB. 23.4% (n = 3598) of these cases were excluded from 
the analysis due to presenting more than 365 days from 
symptoms onset to diagnosis or due to inconsistencies in 
the dates for the beginning of symptoms, first healthcare 
contact or diagnosis, resulting in a final sample of 11,762 
patients. When comparing the included and excluded 
individuals, there were some differences between the 
groups as shown in the Supplementary Table 1.
70.4% (n = 8281) of the patients included in the study 
were male, with mean age of 46.4 years (± standard 
deviation 17.9), ranging from less than 1 to 100 years, 
and with Portugal as the more frequent country of ori-
gin (n = 9901, 84.2%) (Table  1). More than half of the 
PTB cases (n = 6080, 51.7%) were notified in the districts 
of Lisbon (n = 3068, 26.1%) and Porto (n = 3012, 25.6%), 
the two main urban areas of the country (Supplementary 
Table 1).
The survival curves of patient, healthcare and total 
delays are shown in Fig. 1. The curves are similar in shape, 
initially with more patients reaching the event quickly 
and then decelerating over time. Healthcare delay pre-
sented the lowest median delay (8 days, IQR: 1–32 days), 
followed by patient delay (37 days, IQR: 19–71 days), and 
lastly by total delay (62 days, IQR: 38–102 days).
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Table 1 Patient, healthcare and total median delay, interquartile range (IQR) and logrank test (p-value) by clinical and 
sociodemographic variables
Variables Patients Patient delay Healthcare delay Total delay












Sex 0,395 < 0,001 < 0,001
 Male 8281/11762 
(70.4%)
37 (19–71) 7 (1–30) 61 (37–100)
 Female 3481/11762 
(29.6%)
36 (19–70) 11 (2–39) 66 (40–106)
Age < 0,001 < 0,001 < 0,001
 0–4 years 50/11750 (0.4%) 25.5 (17–49) 10.5 (4–44) 47 (32.5–95)
 5–14 years 73/11750 (0.6%) 33 (18–70) 7 (2–21.5) 52 (32–88)
 15–24 years 1109/11750 
(9.4%)
36 (20–65) 6 (1–22) 55 (34–83)
 25–34 years 1951/11750 
(16.6%)
39 (21–74) 7 (1–25) 59 (37–97)
 35–44 years 2682/11750 
(22.8%)
38 (19–74) 6.5 (1–27) 60 (36–99)
 45–54 years 2430/11750 
(20.7%)
40 (20–75) 7 (1–28) 64.5 (38–106)
 55–64 years 1464/11750 
(12.4%)
38 (20–75) 10 (1–36) 68 (40–109)
 > = 65 years 1991/11750 
(16.9%)
30 (14–60) 21 (4–55) 70 (41–112)
Country of origin < 0,001 0.002 0.033
 Portugal 9901/11747 (84.2) 36 (18–69) 9 (1–33) 62 (37–102)
 Country of high 
TB incidence
1752/11747 (14.9) 44 (24–80) 7 (1–27) 66,5 (41–106)
 Country of low 
TB incidence
94/11747 (0.8) 34.5 (18–64) 8 (1–28) 59 (31–99)
Comorbidities
 Chronic renal 
failure
100/11762 (0.9%) < 0,001 0,013 0,316
 Yes 24 (9–42) 21 (4–46) 52 (26–87)
 No 37 (19–71) 8 (1–32) 62 (38–102)
 Oncologic 
diseases
488/11762 (4.1%) 0,001 < 0,001 0,048
 Yes 30 (15–55) 26 (5–55) 66 (42–108)
 No 37 (19–72) 8 (1–31) 62 (37–102)
 Inflammatory 
diseases
107/11572 (0.9%) 0,414 0,036 0,04
 Yes 32 (16–83) 16 (2–48) 79 (42–117)
 No 37 (19–71) 8 (1–33) 62 (38–102)
 Respiratory 
diseases
647/11762 (5.5%) 0,231 < 0,001 0,004
 Yes 33 (14–69) 13 (2–46) 70 (40–113)
 No 37 (19–71) 8 (1–32) 62 (37–102)
 Diabetes 780/11762 (6.6%) 0,929 0,003 0,087
 Yes 38 (19–73) 11 (2–39) 68 (41–111)
 No 37 (19–71) 8 (1–32) 62 (37–102)
 HIV infection 1240/10793 
(11.5%)
< 0,001 < 0,001 < 0,001
 Yes 36 (19–64) 8 (1–27) 56 (35–89)
 No 38 (19–73) 8 (1–33) 64 (38–105)
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Patient delay
The median time between symptom onset and first 
healthcare contact presented an increasing trend over 
the years, ranging from 33 days in 2008 to 44 days in 2017 
(11 days difference) (Fig. 2).
Nearly half of the patients (41.7%, n = 4907) had their 
first healthcare contact within 1 month after symptom 
onset, while more than a quarter of the patients took 
more than 3 months to seek help after symptom onset 
(17.1%, n = 2009) (Fig. 3).
Country of origin, chronic renal failure, oncologic dis-
eases, HIV infection, alcohol abuse, unemployment and 
health professionals exhibited statistically significant 
differences between the survival curves of the groups in 
each variable. Patients from a high TB incidence country, 
with alcohol problems or unemployed presented higher 
median patient delays than patients without these risk 
factors. On the other hand, patients with chronic renal 
failure, oncological diseases, HIV infection or health pro-
fessionals presented a lower median patient delay than 
patients without these risk factors.
In the final multivariate Cox proportional hazard 
model, country of origin [country of high TB incidence 
(0.858) - Reference category: Portugal], alcohol abuse 
(HR 0.91) and unemployment (HR 0.938) presented a sta-
tistically significant association with longer patient delay 
(HR < 1) (Fig. 4 and Table 2). Age [0–4 (HR 1.681), 15–24 
(HR 1.107), ≥65 years (HR 1.124) - Reference category: 
25–34], chronic renal failure (HR 1.485), HIV infection 
(HR 1.188) and being a health professional (HR 1.124) 
presented a statistically significant association with a 
shorter delay time.
Regarding the Schoenfeld residuals, the correlation 
between the residuals and time were tested and found 
that some variables violated the assumption of non-
proportionality. However, even small violations will be 
significant given the large sample size. After visualiza-
tion of the respective scatterplot to inspect the fit of the 
proportional hazard assumption, it was considered that 
the assumption was not violated as the plots do not show 
clear patterns or systematic deviations through time 
(Supplementary Fig. 1).
Table 1 (continued)
Variables Patients Patient delay Healthcare delay Total delay













 Alcohol abuse 1832/11270 
(16.3%)
< 0,001 < 0,001 0,699
 Yes 43 (22–81) 5 (1–21) 62.5 (36–103)
 No 36 (18–68) 9 (1–35) 62 (38–102)
 Drug abuse 1234/11363 
(10.9%)
0,421 < 0,001 0,001
 Yes 38 (19–74) 5 (1–23) 57 (34–95)
 No 37 (19–70) 9 (1–34) 63 (38–103)
Homeless 201/11518 (1.7%) 0,745 < 0,001 0,001
 Yes 39 (20–76) 4 (1–20) 54 (29–90)
 No 37 (19–71) 8 (1–33) 63 (38–103)
Community 
residence
366/11479 (3.2%) 0,099 0,001 < 0,001
 Yes 33 (19–60) 6 (1–22) 53 (33–86)
 No 37 (19–72) 8 (1–33) 63 (38–103)
Unemployment 1891/11762 
(16.1%)
< 0,001 < 0,001 0,357
 Yes 42 (21–79) 5 (1–22) 61 (36–100)
 No 36 (18–70) 9 (1–34) 62 (38–103)
Health profes-
sional
463/11762 (3.9%) 0,001 0,69 0,024
 Yes 30 (16–59) 9 (1–33) 57 (31–98)
 No 37 (19–72) 8 (1–32) 62 (38–102)
IQR interquartile range (Q1-Q3)
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Fig. 1 Survival curves for patient, healthcare and total delays for the 11,762 patients enrolled in the study (2008–2017)
Fig. 2 Annual median days for survival time with confidence intervals (95%CI) by patient, healthcare and total delay (2008–2017)
Page 7 of 13Santos et al. BMC Public Health         (2021) 21:2178  
Fig. 3 Proportion of patients who sought the healthcare services (patient delay), or were diagnosed (healthcare delay and total delay) within 
1 month, between 1 and 2 months, 2 and 3 months and > 3 months
Fig. 4 Hazard ratios (HR) with confidence intervals (95%CI) for the variables included in the final multivariate Cox proportional hazard model for 
patient, healthcare and total delay. *Reference category. HR values> 1 indicate a greater risk of having the event per unit of time, therefore a shorter 
time until approaching the healthcare services (patient delay) or diagnosis (healthcare and total delay)
Page 8 of 13Santos et al. BMC Public Health         (2021) 21:2178 
Healthcare delay
The median time between first healthcare con-
tact and diagnosis was relatively constant between 
2008 and 2017, increasing one day during this period 
(2008–9 days, 2017–10 days) (Fig. 2).
Most of the patients (73.5%, n = 8650) had a diagnosis 
within 1 month after first healthcare contact, with only 
7.1% (n = 837) being diagnosed more than 3 months 
after seeking medical aid (Fig. 3).
Healthcare delay presented the highest number of 
risk factors with significant differences between the 
survival curves of their subgroups, with being a health 
professional the only variable that did not present a 
statistically significant difference (p = 0.69) - Table  1. 
Female patients, Portugal-born patients, patients with 
chronic renal failure, diabetes, oncological, inflamma-
tory or respiratory diseases presented higher median 
healthcare delays than patients without these risk fac-
tors. In contrast, patients with alcohol or drug prob-
lems, homeless, residing in a community residence, or 
unemployed presented a lower median healthcare delay 
than patients without these risk factors.
In the final multivariate Cox model, sex [female (HR 
0.839) - Reference category: male], age ≥ 45 years, onco-
logic diseases (HR 0.829) and respiratory diseases (HR 
0.905) were identified as presenting a statistically sig-
nificant association with a longer healthcare delay (Fig. 4 
and Table  2). Conversely, age [15–24 years (HR 1.118) 
Table 2 Hazard ratios and confidence intervals for the variables included in the final multivariate Cox proportional hazard model by 
patient, healthcare and total delay
a Reference category, HR Hazards ratio, CI confidence interval
HR > 1 indicate a higher risk of having the event per unit of time, i.e., a shorter time until approaching the healthcare services (patient delay) or diagnosis (healthcare 
and total delay)
Patient delay (Final model) Healthcare delay (Final model) Total delay (Final model)
Variables HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
Sex  (Malea)
 Female 0.839 (0.804–0.875) < 0.001 0.874 (0.837–0.913) < 0.001
Age group (25–34  yearsa)
 0–4 years 1.681 (1.184–2.385) 0.004 0,807 (0.61–1.07) 0.136 1091 (0.769–1.549) 0.624
 5–14 years 1.087 (0.84–1.406) 0.527 1052 (0.831–1.332) 0.674 1.177 (0.909–1.523) 0.216
 15–24 years 1.107 (1.025–1.197) 0.01 1.118 (1.037–1.206) 0.004 1.219 (1.128–1.318) < 0.001
 35–44 years 0.999 (0.938–1.063) 0.965 0.946 (0.89–1.005) 0.074 0,957 (0.9–1.018) 0.166
 45–54 years 0.94 (0.882–1.002) 0.059 0.896 (0.842–0.955) 0.001 0.881
(0.827–0.938)
< 0.001
 55–64 years 0.932 (0.866–1.003) 0.059 0.808 (0.753–0.868) < 0.001 0.817 (0.76–0.879) < 0.001
 > = 65 years 1.124 (1.049–1.204) 0.001 0.678 (0.634–0.725) < 0.001 0.813 (0.76–0.87) < 0.001
Country of origin  (Portugala)
 Country of high TB incidence 0.858 (0.811–0.907) < 0.001 0.893 (0.845–0.943) < 0.001
 Country of low TB incidence 0.975 (0.784–1.213) 0.821 1.041 (0.838–1.293) 0.719
Comorbidities (Yes/Noa)
 Chronic renal failure 1.485 (1.19–1.852) < 0.001
 Oncologic diseases 0.829 (0.754–0.911) < 0.001
Inflammatory diseases
 Respiratory diseases 0.905 (0.833–0.984) 0.02
Diabetes
 HIV infection 1.188 (1.114–1.267) < 0.001 1.219 (1.144–1.299) < 0.001
Substance abuse (Yes/Noa)
 Alcohol abuse 0.91 (0.862–0.961) 0.001 1.197 (1.134–1.264) < 0.001
Drug abuse
Homeless (Yes/Noa)
 Community residence (Yes/Noa) 1.239 (1.11–1.38) < 0.001 1.161 (1.039–1.298) 0.008
 Unemployment (Yes/Noa) 0.938 (0.888–0.991) 0.022 1.077
(1.021–1.135)
0.006
 Health professional (Yes/Noa) 1.124 (1.015–1.246) 0.025 1.126 (1.018–1.246) 0.022
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- Reference category: 25–34], alcohol abuse (HR 1.197), 
community residence (HR 1.239) and unemployment 
(HR 1.077) were associated with a shorter healthcare 
delay.
Regarding the Schoenfeld residuals, was found that 
some variables violated the assumption of non-pro-
portionality. However, after visual inspection it was 
considered that the assumption was not violated (Supple-
mentary Fig. 2).
Total delay
Median total delay, as observed in patient delay, pre-
sented a steady increase between 2008 and 2017 that 
resulted in 11 days increase during this period (2008–
59 days, 2017–70 days) (Fig. 2).
Just over a quarter of the patients (17.1%, n = 2012) 
were diagnosed within 1 month after symptom onset, 
while more than half (51.5%, n = 6054) were diagnosed 
more than 2 months after symptom onset (Fig.  3). Over 
the years, the proportion of patients with a total delay 
of more than 3 months has gradually increased while 
patients with a delay of less than 1 month have been 
decreasing (Fig. 5).
Sex, age, country of origin, oncologic diseases, inflam-
matory diseases, respiratory diseases, HIV infection, 
drug abuse, homeless, community residence and being a 
health professional exhibited statistically significant dif-
ferences between the survival curves of their subgroups 
(Table 1). Female patients, patients from a high TB inci-
dence country, patients with oncological, inflammatory 
or respiratory diseases presented higher median total 
delays than patients without these risk factors. On the 
contrary, patients with drug problems, homeless, residing 
in a community residence, or health professionals pre-
sented a lower median total delay than patients without 
these risk factors.
In the final multivariate Cox model, sex [female (HR 
0.874) - Reference category: male], age ≥ 45 years and 
country of origin [country of high TB incidence (0.893) 
- Reference category: Portugal] presented a statistically 
significant association with a longer total delay (Fig.  4 
and Table  2). Age [15–24 years (HR 1.219) - Reference 
category: 25–34], HIV infection (HR 1.219), community 
residence (HR 1.161) and being a health professional (HR 
1.126) presented a statistically significant association 
with a shorter total delay.
Regarding the Schoenfeld residuals, some variables vio-
lated the assumption of non-proportionality. However, 
after visual inspection it was considered that the assump-
tion was not violated as the plots do not show clear 
patterns or systematic deviations through time (Supple-
mentary Fig. 3).
Discussion
In our study, median healthcare delay was 8 days, 
a lower value than the one exhibited by the patient 
delay (37 days), with total delay presenting a median 
delay of 62 days between symptom onset and diagno-
sis. These results for patient and total delays are close 
to those obtained in a systematic review that summa-
rized delays from low and high-income countries [11], 
however we observed a shorter healthcare delay (8 vs 
21.5 days). This difference between healthcare delays 
may reflect the heterogeneity of the healthcare systems 
associated with the studies included in the systematic 
review. In Portugal, a study that evaluated the delays 
Fig. 5 Annual proportion of patients diagnosed within 1 month, between 1 and 2 months, 2 and 3 months and > 3 months after symptoms onset
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in pulmonary and extrapulmonary TB cases notified 
between 2010 and 2014 [23], also revealed similar val-
ues for median patient delay (33 days) and total delay 
(68 days) but the median healthcare delay was double of 
ours (17 days). Loutet et al. [30] established that health-
care delay was significantly longer among patients with 
extrapulmonary TB than those with pulmonary disease, 
since diagnosis of extrapulmonary TB is often delayed 
or overlooked due to misleading clinical presentation 
or poor performance of available diagnostic tests [31]. 
Thus, the contrast in median healthcare delays between 
the studies may reflect the inclusion of extrapulmonary 
TB cases in the analysis. Nevertheless, our results sup-
port those obtained in studies from other countries, 
where median patient delay is consistently higher than 
the healthcare delay [20, 30, 32–34].
Our results also show that Portugal is far from reach-
ing the ideal time of 3 to 4 weeks [12] between the 
symptom onset and diagnosis (62 days vs 30 days). 
More than half of the cases of PTB (82.9%) notified in 
Portugal between 2008 and 2017 had a delay of more 
than 1 month between symptoms onset and diagnosis, 
with the proportion of patients that were diagnosed 
more than 3 months after symptoms onset display-
ing an increase trend during this period. These results 
are reflected in the median patient and total delays 
steady increase over the years, resulting in an increase 
of 11 days between 2007 and 2018. Healthcare delay 
remained relatively constant, however displaying an 
increase of 1 day between 2007 and 2018.
These findings suggest that delaying seeking help from 
the healthcare providers is the driving force behind the 
delay in diagnosing and beginning of treatment. Longer 
delays between symptoms onset and reaching for help 
from the healthcare services as an impact at an individual 
level, by increasing the patient risk of morbidity and mor-
tality, and at a population level, by increasing the risk of 
spreading the disease through the community. Bello et al. 
[6] systematic review also shown a considerable delay in 
patients seeking help from the healthcare services. This 
delay can occur as a consequence of different factors such 
as the time it takes the patients to realize the symptoms 
and understand that they are ill, self-medication, need-
ing time to think about seeking help from a health pro-
fessional, or being able to overcome social, personal and 
physical barriers to obtain the necessary care [6, 33, 35]. 
Thus, in order to improve the control of the TB epidemic 
and reduce the time between the symptoms onset and 
TB diagnosis, strategies with an impact on the patient’s 
delay should be considered. However, these strategies 
should not be directed only at the patient (e.g., increase 
literacy about TB) but also directed to the healthcare sys-
tem, and how the healthcare services and professionals 
can help patients reach the healthcare system in a shorter 
time [11, 12, 15].
Several clinical and sociodemographic factors were 
associated with delayed diagnosis, which could affect the 
patient, healthcare and/or total delay. Female patients 
experienced a significant longer healthcare and total 
delay when compared to male patients, as observed in 
other similar studies [30, 32, 36–38]. However, some 
studies have reached the opposite conclusions [14, 39] 
and others reported no statistically significant associa-
tion between sex and late TB diagnosis and treatment 
[10, 20, 40]. These discrepancies may reflect differences 
in health seeking behaviors and gender roles between the 
different countries. PTB was investigated more readily 
in male patients, although female patients did not seek 
care later than men. One explanation could be that male 
patients are considered to have a higher risk of develop-
ing TB than female patients, currently the proportion 
of male:female TB cases is 2:1 [4], which may lead to a 
greater suspicion of TB in male patients with suggestive 
symptoms and, consequently, an earlier diagnosis. Fur-
ther studies should be developed in order to understand 
the reasons for the delay in recognizing the disease in 
women, in order to establish strategies aimed at reducing 
the time between the first consultation and the diagnosis.
Age was another risk factor for longer healthcare and 
total delays, with the likelihood of longer delays increas-
ing as age progressed. Patients over 45 years presented a 
significant association with a longer time between first 
contact with the healthcare system and a TB diagnosis. 
Other studies have also found this association [20, 30, 
32, 33, 41], where older patients were more commonly 
misdiagnosed than younger patients. Despite not hav-
ing significant delays in terms of seeking help from the 
healthcare services, older patients may present greater 
frequency of intercurrent or co-existing diseases or 
comorbidities that may decrease the suspicion of a TB 
diagnosis or make it more difficult to recognize TB symp-
toms [20, 30, 32]. Also, elderly patients often do not pre-
sent with typical TB symptoms [10, 32, 42, 43], leading to 
older patients deteriorate without TB being considered 
and becoming a source of transmission in the community 
[44]. Harris et al. [45] in their study assessed the conse-
quences of a long delay in TB diagnosis among elderly 
patients, which increased the likelihood of transmis-
sion and enhanced the severity of the TB disease and of 
the co-morbidities. Therefore, increased knowledge and 
awareness of TB, especially among professionals working 
closely with older people could help reduce transmission 
and also morbidity and mortality caused by the disease.
Foreign-born TB cases, more specifically from coun-
tries with a high TB incidence, were more likely to have 
a delay in accessing healthcare services when compared 
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with Portugal-born patients. Migrants’ social, legal and 
economic circumstances can have a detrimental effect 
on accessing the healthcare system. Language barriers, 
organizational challenges, fear of immigration authori-
ties, unfavorable socioeconomic conditions, poor aware-
ness of symptoms and stigma [46, 47] are some of the 
difficulties that migrants face and that may justify a 
longer time to seek help from the healthcare service. 
On the other hand, Portugal-born patients experienced 
longer healthcare delays than foreign-born patients did. 
Possibly because healthcare professionals will have a 
higher index of suspicion of TB in patients with sugges-
tive symptoms that are from countries with high TB inci-
dence than Portugal-born, resulting in shorter healthcare 
delays. This finding is consistent with studies carried out 
in other countries low incidence countries [20, 48, 49].
Alcohol abuse and unemployment presented an asso-
ciation with longer delays, more specifically between 
beginning of symptoms and seeking help from the 
healthcare services. Previous studies [23, 50, 51] have 
established that patients with addictions are less likely to 
visit the healthcare services in a timely manner. This may 
result from the fact that patients who consume alcohol in 
excess may not seek, or easily have access to, healthcare 
providers when they start presenting symptoms and real-
ize they are ill, resulting in delayed diagnosis and more 
advanced disease [52]. Notwithstanding, when these 
patients are first seen by a healthcare professional, the 
time to diagnosis is lower because of a high suspicion 
index [23]. Regarding unemployment, other studies have 
also shown that unemployment is an risk factor for delay 
in seeking treatment [18, 53, 54], as these patients are dis-
courage by their economic situation from seeking health-
care in due time. Furthers studies should be conducted to 
support the design of interventions aimed at reducing the 
delay of these patients in reaching the healthcare system.
In our study, oncologic and respiratory diseases were 
associated with a longer healthcare delay. The coexist-
ence of other diseases may delay the TB diagnosis, since 
they may have similar symptoms or even alter the typical 
symptoms indicative of TB. For example, sarcoidosis is a 
granulomatous disease with a similar clinical, radiologi-
cal and histologic presentation as TB, making it difficult 
to identify a concurrent TB infection [55]. In addition, 
the non-specific nature of TB signs and symptoms, com-
bined with the low TB incidence in Portugal, may lead to 
think to other causes such as pneumonia, bronchitis or 
asthma before TB.
Our study presents some limitations. Due to the large 
number of inconsistent or missing data, we were unable 
to calculate the patient, healthcare and/or total delay 
for 23.4% of the notified PTB patients, resulting in their 
exclusion from the analysis. Analyzing the differences 
between included and excluded patients (Supplementary 
Table  1), significant differences were identified between 
these patients. Excluded patients tended to be older, 
presenting a higher proportion of several comorbidi-
ties (oncologic and respiratory diseases, HIV infection) 
and disadvantaged socioeconomic conditions (homeless 
and residing in a community residence). Considering 
that some variables were associated with longer patient, 
healthcare and/or total delay, it is difficult to ascertain 
whether excluding these patients might have led to an 
under or overestimation of the diagnostic delay and, 
consequently, biased some of the identified associations. 
However, given that the differences between groups were 
small, we believe that this did not substantially influence 
our results. Furthermore, it is important to be careful 
when interpreting these results, as large sample sizes tend 
to produce smaller p-values. The presence of variables 
based on patient self-report (e.g., alcohol and drug abuse) 
may have led to a less accurate estimate of the impact of 
these variables in the delays. The date of symptoms onset 
was attained retrospectively, this fact may have caused 
patient delays to be affected by memory bias.
However, our analysis has different strengths. The study 
involved a considerable number of patients with different 
clinical and sociodemographic characteristics giving a 
broad and extensive view of the population delays, hop-
ing to contribute significantly to a better understanding 
of patient, health and total delays in Portugal. The sepa-
rate analysis of the patient and healthcare delays allowed 
us to observe whether the different risk factors included 
in the analysis affect each of the delays differently. This 
allowed us to recognize that the factors affect each of 
these dimensions differently, relevant information for the 
development of more targeted strategies to reduce each 
of the delays.
Conclusion
Despite the improvement in the Portuguese health ser-
vice over the last decades, the time between symptom 
onset and a TB diagnosis has increased over the years, 
furthering the transmission and occurrence of new cases 
of infection in the community and increasing the prob-
ability of disease progression, morbidity and mortality of 
infected patients.
In the present study, we observed that the time 
between symptom onset and first contact with the health 
system (patient delay) has increased over the years. This 
result highlights the need to develop strategies to reduce 
patient delay, such as improving health literacy, especially 
concerning TB, and emphasizing the importance of seek-
ing healthcare services in a timely manner.
Several factors associated with delayed diagnosis 
were identified, some associated with a longer patient 
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delay (alcohol abuse, unemployment and being from a 
high TB incidence country), while others with a longer 
healthcare delay (being female, having more than 
45 years, oncologic and respiratory diseases). Identify-
ing these factors allows the development of targeted 
public health policies and strategies, reaching popula-
tion groups that present a significant delay in the diag-
nosis of TB and, consequently, help reduce the chain 
of transmission. One example is the implementation of 
policies and strategies to facilitate health care access to 
foreign-born patients, which would have benefits for 
both the potentially marginalized communities and the 
general population.
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